This is the company’s fourth biosimilar launch in recent times
Pune-based technology-oriented biotechnology company Enzene Biosciences has begun commercial supplies of Adalimumab for treating Ankylosis Spondylitis (AS) and Rheumatoid Arthritis (RA). This is the company’s fourth biosimilar launch in recent times and the company believes that this first commercial launch using continuous manufacturing technology will help in reducing the cost of RA treatment for millions of patients across India.
Dr Himanshu Gadgil, CEO, Enzene Biosciences, “We have been working on this novel fully integrated platform for the last six years and the commercialisation of Adalimumab is a validation of our innovation-based work culture. Enzene is planning to expand global access to this platform through our CDMO vertical.
Adalimumab development included comparative efficacy and safety studies in patients with Ankylosing spondylitis, also known as Marie-Strumpell disease or Bechterew’s disease. This is the fourth Biosimilar launch for the company in the last eighteen months.
